Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial
Health Engagement for Rural Ohio Cancer Survivors (HERO-C)
Studieoversikt
Status
Forhold
- Anatomisk stadium I brystkreft AJCC v8
- Anatomisk stadium II brystkreft AJCC v8
- Anatomisk stadium III brystkreft AJCC v8
- Endometriekarsinom
- Fase III Uterine Corpus Carcinoma eller Carcinosarcoma AJCC V8
- Fase I Uterine Corpus Carcinoma eller Carcinosarcoma AJCC V8
- Fase II Uterine Corpus Carcinoma eller Carcinosarcoma AJCC V8
Intervensjon / Behandling
- Annen: Spørreskjemaadministrasjon
- Fremgangsmåte: Bioprøvesamling
- Annen: Aerobic Exercise
- Annen: Dietary Intervention
- Annen: Discussion
- Annen: Internet-Based Intervention
- Annen: Resistance Training
- Annen: Supportive Care
- Annen: Supportive Care
- Annen: Goal Setting
- Annen: Medical Device Usage and Evaluation
- Atferdsmessig: Smartphone Application-based Intervention
- Fremgangsmåte: Tailored Intervention
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. To determine the feasibility of an mHealth + EMA intervention in addition to the web-based lifestyle program with remote outcome assessments among rural breast and endometrial cancer survivors. (Aim 1) Ia. To identify rural cancer survivors' perspectives and unique needs/challenges of participating in a web-based lifestyle program via focus groups pre- and post-intervention (n=20); (Aim 1a) Ib. To determine the feasibility of mHealth + EMA among early non-responders (week 5-26); (Aim 1b) Ic. To determine the feasibility of remote outcome assessments. (Aim 1c) II. To determine the preliminary efficacy of the additional mHealth + EMA intervention for early non-responders from the web-based lifestyle program (within-person change from week 5-26). (Aim 2)
EXPLORATORY OBJECTIVE:
I. To explore the differences in metabolomic, inflammatory, behavioral, and psychosocial factors between early responders and early non-responders at baseline, month 1 and month 6.
OUTLINE:
PHASE I (WEEKS 1-4): Patients complete self-paced web-based lifestyle program modules over 45-90 minutes weekly for 4 weeks. Patients adhere to a personalized diet meeting American Institute of Cancer Research (AICR) guidelines and receive access to online resources, including AICR resources, online cooking class videos, healthy eating recipes and tips. Patients participate in moderate-intensity aerobic physical activity over 10-30 minutes on 5 days weekly and resistance training over 30 minutes on 2-3 times weekly.
PHASE II (WEEKS 5-26): Patients are assigned to 1 of 2 groups based on Phase I progress.
GROUP I (EARLY RESPONDER): Patients continue web-based program modules, exercise program and diet recommendations as in Phase I. Patients also attend virtual group sessions over 45-50 minutes weekly for weeks 5-26.
GROUP II (EARLY NON-RESPONDER): Patients continue web-based program modules, exercise program and diet recommendations as in Phase I. Patients also set goals for behavioral changes weekly and receive just-in-time adaptive interventions (JITAI) tailored resource components via mHealth + EMA during weeks 5-26. Patients wear a physical activity tracker daily and receive access to the Fitbit application (App).
Patients may also participate in a focus group over 30-45 minutes on study. Additionally, patients undergo urine and blood sample collection throughout the study.
After completion of study intervention, patients may follow up in 6 months.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: The Ohio State University Comprehensive Cancer Center
- Telefonnummer: 800-293-5066
- E-post: OSUCCCClinicaltrials@osumc.edu
Studiesteder
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43210
- Ohio State University Comprehensive Cancer Center
-
Ta kontakt med:
- Xiaochen Zhang, PhD
- Telefonnummer: 614-685-0624
- E-post: Xiaochen.Zhang@osumc.edu
-
Hovedetterforsker:
- Xiaochen Zhang, PhD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Body mass index (BMI) ≥ 25kg/m^2
- Age: 40-69 years
- 1-5 years post-diagnosis of stage I-III postmenopausal breast cancer or stage I-III endometrial cancer
- No known evidence of recurrence (local or distant) or second, primary cancer
- No prior history of new other malignancy since their breast or endometrial cancer diagnosis (other than non-melanoma skin cancer)
- Not currently participating in any weight loss programs, no personal trainer, and not meeting the physical activity guidelines
- No use of any anti-obesity medications in the last 6 months and no plan to start anti-obesity medications during the study period
- The ability to walk two blocks without a walker or cane
- The ability to speak and read English
- Have access to internet with a computer, tablet, or smart phone
- Live in rural counties in Ohio and not planning to move away during the study
- Are not pregnant, breastfeeding or less than 12-month post-partum and do not plan to become pregnant during the study
Exclusion Criteria:
- Severe medical conditions, such as unstable cardiovascular disease or digestive disorders, that would preclude physical activity and dietary intervention
- Lack of physician clearance if determined necessary by the Physical Activity Readiness Questionnaire (PAR-Q+)
- Acute physical limitations for unsupervised exercises at home
- Unable to give informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Group I (web-based lifestyle program, virtual group)
PHASE I (WEEKS 1-4): Patients complete self-paced web-based lifestyle program modules over 45-90 minutes weekly for 4 weeks. Patients adhere to a personalized diet meeting AICR guidelines and receive access to online resources, including AICR resources, online cooking class videos, healthy eating recipes and tips. Patients participate in moderate-intensity aerobic physical activity over 10-30 minutes on 5 days weekly and resistance training over 30 minutes on 2-3 times weekly. PHASE II (WEEKS 5-26): Patients continue web-based program modules, exercise program and diet recommendations as in Phase I. Patients also attend virtual group sessions over 45-50 minutes weekly for weeks 5-26. Patients may also participate in a focus group over 30-45 minutes on study. Additionally, patients undergo urine and blood sample collection throughout the study. |
Hjelpestudier
Gjennomgå urin- og blodprøvetaking
Andre navn:
Participate in moderate-intensity aerobic physical activity
Andre navn:
Adhere to a personalized diet
Andre navn:
Participate in a focus group
Andre navn:
Complete self-paced web-based lifestyle program modules
Participate in resistance training
Andre navn:
Receive access to online resources
Andre navn:
Attend virtual group sessions
Andre navn:
|
|
Eksperimentell: Group II (web-based lifestyle, JITAI)
PHASE I (WEEKS 1-4): Patients complete self-paced web-based lifestyle program modules over 45-90 minutes weekly for 4 weeks. Patients adhere to a personalized diet meeting AICR guidelines and receive access to online resources, including AICR resources, online cooking class videos, healthy eating recipes and tips. Patients participate in moderate-intensity aerobic physical activity over 10-30 minutes on 5 days weekly and resistance training over 30 minutes on 2-3 times weekly. PHASE II (WEEKS 5-26): Patients continue web-based program modules, exercise program and diet recommendations as in Phase I. Patients also set goals for behavioral changes weekly and receive JITAI tailored resource components via mHealth + EMA during weeks 5-26. Patients wear a physical activity tracker daily and receive access to the Fitbit App. Patients may also participate in a focus group over 30-45 minutes on study. Patients undergo urine and blood sample collection throughout the study. |
Hjelpestudier
Gjennomgå urin- og blodprøvetaking
Andre navn:
Participate in moderate-intensity aerobic physical activity
Andre navn:
Adhere to a personalized diet
Andre navn:
Participate in a focus group
Andre navn:
Complete self-paced web-based lifestyle program modules
Participate in resistance training
Andre navn:
Receive access to online resources
Andre navn:
Attend virtual group sessions
Andre navn:
Set goals for behavioral changes
Wear a physical activity tracker
Receive access to the Fitbit app
Andre navn:
Receive JITAI tailored resource components
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Preferences, needs and satisfaction (Aim 1a)
Tidsramme: At pre- and post-intervention, assessed up to week 26
|
Focus groups will be audio recorded through online videoconference (e.g.
Teams) and transcribed using NVivo.
Content analysis will be conducted to identify patterns, themes, and perspectives from participants using NVivo coding or similar software.
When possible, the frequency, intensity, and context of certain perspectives will be described.
Similarly, thematic analysis will be conducted using NVivo to identify themes (e.g., likes/dislikes, motivations, expectations) and mapped to potential intervention components.
|
At pre- and post-intervention, assessed up to week 26
|
|
Percentage of early non-responders who complete the mobile Health + ecological momentary assessment intervention (Aim 1b)
Tidsramme: Up to week 26
|
Will report the frequency, proportion, and 95% confidence intervals (CIs) of early non-responders who completed the intervention.
|
Up to week 26
|
|
Percentage of all participants who complete all assessments (Aim 1c)
Tidsramme: Up to week 26
|
Will report the frequency, proportion, and 95% CIs of all participants who completed outcome assessments.
|
Up to week 26
|
|
Changes in weight (Aim 2)
Tidsramme: At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
Linear mixed models will be used to account for repeated measures, with random effects for the individual.
The linear mixed models will use all available data under a missing-at-random assumption and will assess potential attrition bias by comparing baseline/week 4 characteristics of completers versus non-completers, with sensitivity analyses is missingness appears outcome-related.
Will report the preliminary effect size as within-person changes on weight (from week 4 to week 26).
|
At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
|
Changes in muscle mass (Aim 2)
Tidsramme: At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
Will estimate the preliminary effect size using linear mixed models.
|
At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
|
Changes in metabolic profiles (Aim 2)
Tidsramme: At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
Will estimate the preliminary effect size using linear mixed models.
|
At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
|
Changes in inflammatory markers (Aim 2)
Tidsramme: At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
Will estimate the preliminary effect size using linear mixed models.
|
At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
|
Changes in behaviors (Aim 2)
Tidsramme: At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
Will estimate the preliminary effect size using linear mixed models.
|
At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Xiaochen Zhang, PhD, Ohio State University Comprehensive Cancer Center
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Neoplasmer etter histologisk type
- Livmorsykdommer
- Kjønnssykdommer, kvinner
- Genitale neoplasmer, kvinnelige
- Uterine neoplasmer
- Sarkom
- Neoplasmer, bindevev og mykt vev
- Neoplasmer, komplekse og blandede
- Endometriale neoplasmer
- Karsinosarkom
- Organisasjon og administrasjon
- Health Services Administration
- Motorisk aktivitet
- Bevegelse
- Muskel- og skjelettfysiologiske fenomener
- Muskel- og skjelett og nevrale fysiologiske fenomener
- Undersøkelsesteknikker
- Terapeutikk
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Fysioterapi -modaliteter
- Pasientbehandling
- Helsetjenester
- Helsetjenester arbeidsstyrke og tjenester
- Treningsterapi
- Rehabilitering
- Ettervern
- Kontinuitet i pasientbehandling
- Ernæringsterapi
- Fysisk kondisjonering, menneskelig
- Øvelse
- Palliativ omsorg
- Prøvehåndtering
- Motstandstrening
- Kostholdsterapi
- Organisatoriske mål
Andre studie-ID-numre
- OSU-26016
- NCI-2026-05189 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- STUDY20252952
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .